![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
"The Value of Control Conditions for Evaluating Pharmacogenetic Effects." Pharmacogenomics, 16(18), pp. 2005–2006
Financial & competing interests disclosure
L-S Chen receives support from NIH (K08 DA030398, R01 DA038076). LJ Bierut receives support from NIH (R01 DA036583, R01 DA025888, K02 DA021237). TB Baker receives support from NIH (P50 CA84724, K05 CA139871, P50 DA19706). LJ Bierut is listed as an inventor on issued US Patent 8,080,371, ‘Markers for Addiction’ covering the use of certain SNPs in determining the diagnosis, prognosis, and treatment of addiction. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of thismanuscript.
Additional information
Funding
L-S Chen receives support from NIH (K08 DA030398, R01 DA038076). LJ Bierut receives support from NIH (R01 DA036583, R01 DA025888, K02 DA021237). TB Baker receives support from NIH (P50 CA84724, K05 CA139871, P50 DA19706). LJ Bierut is listed as an inventor on issued US Patent 8,080,371, ‘Markers for Addiction’ covering the use of certain SNPs in determining the diagnosis, prognosis, and treatment of addiction. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of thismanuscript.